Search

Your search keyword '"Papaioannou, Andriana I."' showing total 516 results
Start Over Author "Papaioannou, Andriana I."
516 results on '"Papaioannou, Andriana I."'

1. International Variation in Severe Exacerbation Rates in Patients With Severe Asthma

Author

Lee, Tae Yoon, Price, David, Yadav, Chandra Prakash, Roy, Rupsa, Lim, Laura Huey Mien, Wang, Eileen, Wechsler, Michael E., Jackson, David J., Busby, John, Heaney, Liam G., Pfeffer, Paul E., Mahboub, Bassam, Perng (Steve), Diahn-Warng, Cosio, Borja G., Perez-de-Llano, Luis, Al-Lehebi, Riyad, Larenas-Linnemann, Désirée, Al-Ahmad, Mona, Rhee, Chin Kook, Iwanaga, Takashi, Heffler, Enrico, Canonica, Giorgio Walter, Costello, Richard, Papadopoulos, Nikolaos G., Papaioannou, Andriana I., Porsbjerg, Celeste M., Torres-Duque, Carlos A., Christoff, George C., Popov, Todor A., Hew, Mark, Peters, Matthew, Gibson, Peter G., Maspero, Jorge, Bergeron, Celine, Cerda, Saraid, Contreras-Contreras, Elvia Angelica, Chen, Wenjia, and Sadatsafavi, Mohsen

Published
2024
Full Text
View/download PDF

2. Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma

Author

Perez-de-Llano, Luis, Scelo, Ghislaine, Canonica, G. Walter, Chen, Wenjia, Henley, William, Larenas-Linnemann, Désirée, Peters, Matthew J., Pfeffer, Paul E., Tran, Trung N., Ulrik, Charlotte Suppli, Popov, Todor A., Sadatsafavi, Mohsen, Hew, Mark, Máspero, Jorge, Gibson, Peter G., Christoff, George C., Fitzgerald, J. Mark, Torres-Duque, Carlos A., Porsbjerg, Celeste M., Papadopoulos, Nikolaos G., Papaioannou, Andriana I., Heffler, Enrico, Iwanaga, Takashi, Al-Ahmad, Mona, Kuna, Piotr, Fonseca, João A., Al-Lehebi, Riyad, Rhee, Chin Kook, Koh, Mariko Siyue, Cosio, Borja G., Perng (Steve), Diahn-Warng, Mahboub, Bassam, Menzies-Gow, Andrew N., Jackson, David J., Busby, John, Heaney, Liam G., Patel, Pujan H., Wang, Eileen, Wechsler, Michael E., Altraja, Alan, Lehtimäki, Lauri, Bourdin, Arnaud, Bjermer, Leif, Bulathsinhala, Lakmini, Carter, Victoria, Murray, Ruth, Beastall, Aaron, Denton, Eve, and Price, David B.

Published
2024
Full Text
View/download PDF

4. Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry

Author

Scelo, Ghislaine, Torres-Duque, Carlos A., Maspero, Jorge, Tran, Trung N., Murray, Ruth, Martin, Neil, Menzies-Gow, Andrew N., Hew, Mark, Peters, Matthew J., Gibson, Peter G., Christoff, George C., Popov, Todor A., Côté, Andréanne, Bergeron, Celine, Dorscheid, Delbert, FitzGerald, J. Mark, Chapman, Kenneth R., Boulet, Louis Philippe, Bhutani, Mohit, Sadatsafavi, Mohsen, Jiménez-Maldonado, Libardo, Duran-Silva, Mauricio, Rodriguez, Bellanid, Celis-Preciado, Carlos Andres, Cano-Rosales, Diana Jimena, Solarte, Ivan, Fernandez-Sanchez, Maria Jose, Parada-Tovar, Patricia, von Bülow, Anna, Bjerrum, Anne Sofie, Ulrik, Charlotte S., Assing, Karin Dahl, Rasmussen, Linda Makowska, Hansen, Susanne, Altraja, Alan, Bourdin, Arnaud, Taille, Camille, Charriot, Jeremy, Roche, Nicolas, Papaioannou, Andriana I., Kostikas, Konstantinos, Papadopoulos, Nikolaos G., Salvi, Sundeep, Long, Deirdre, Mitchell, Patrick D., Costello, Richard, Sirena, Concetta, Cardini, Cristina, Heffler, Enrico, Puggioni, Francesca, Canonica, Giorgio Walter, Guida, Giuseppe, Iwanaga, Takashi, Al-Ahmad, Mona, Linnemann, Désirée Larenas, Garcia, Ulises, Kuna, Piotr, Fonseca, João A., Al-Lehebi, Riyad, Koh, Mariko Siyue, Rhee, Chin Kook, Cosio, Borja G., de Llano, Luis Perez, Perng (Steve), Diahn-Warng, Huang, Erick Wan-Chun, Wang, Hao-Chien, Tsai, Ming-Ju, Mahboub, Bassam, Salameh, Laila Ibraheem Jaber, Jackson, David, Busby, John, Heaney, Liam G., Pfeffer, Paul, Goddard, Amanda Grippen, Wang, Eileen, Hoyte, Flavia, Wechsler, Michael E., Chapman, Nicholas, Katial, Rohit, Carter, Victoria, Bulathsinhala, Lakmini, Eleangovan, Neva, Ariti, Con, Lyu, Juntao, Price, David B., and Porsbjerg, Celeste

Published
2024
Full Text
View/download PDF

5. Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry

Author

Chen, Wenjia, Tran, Trung N., Sadatsafavi, Mohsen, Murray, Ruth, Wong, Nigel Chong Boon, Ali, Nasloon, Ariti, Con, Bulathsinhala, Lakmini, Gil, Esther Garcia, FitzGerald, J. Mark, Alacqua, Marianna, Al-Ahmad, Mona, Altraja, Alan, Al-Lehebi, Riyad, Bhutani, Mohit, Bjermer, Leif, Bjerrum, Anne-Sofie, Bourdin, Arnaud, von Bülow, Anna, Busby, John, Canonica, Giorgio Walter, Carter, Victoria, Christoff, George C., Cosio, Borja G., Costello, Richard W., Fonseca, João A., Gibson, Peter G., Yoo, Kwang-Ha, Heaney, Liam G., Heffler, Enrico, Hew, Mark, Hilberg, Ole, Hoyte, Flavia, Iwanaga, Takashi, Jackson, David J., Jones, Rupert C., Koh, Mariko Siyue, Kuna, Piotr, Larenas-Linnemann, Désirée, Lehmann, Sverre, Lehtimäki, Lauri, Lyu, Juntao, Mahboub, Bassam, Maspero, Jorge, Menzies-Gow, Andrew N., Newell, Anthony, Sirena, Concetta, Papadopoulos, Nikolaos G., Papaioannou, Andriana I., Perez-de-Llano, Luis, Perng (Steve), Diahn-Warng, Peters, Matthew, Pfeffer, Paul E., Porsbjerg, Celeste M., Popov, Todor A., Rhee, Chin Kook, Salvi, Sundeep, Taillé, Camille, Taube, Christian, Torres-Duque, Carlos A., Ulrik, Charlotte, Ra, Seung-Won, Wang, Eileen, Wechsler, Michael E., and Price, David B.

Published
2023
Full Text
View/download PDF

6. SARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics

Author

Papaioannou, Andriana I., Fouka, Evangelia, Tzanakis, Nikolaos, Antoniou, Katerina, Samitas, Konstantinos, Zervas, Eleftherios, Kostikas, Konstantinos, Bartziokas, Konstantinos, Porpodis, Konstantinos, Papakosta, Despoina, Tzouvelekis, Argyris, Gerogianni, Irini, Kotsiou, Ourania, Makris, Michael, Rovina, Nikoletta, Vlachou, Garyfallia, Markatos, Miltiadis, Vittorakis, Stelios, Katsoulis, Konstantinos, Papanikolaou, Ilias, Afthinos, Andreas, Katsaounou, Paraskevi, Steiropoulos, Paschalis, Latsios, Dimitrios, Dimakou, Katerina, Koukidou, Sofia, Hillas, Georgios, Tryfon, Stavros, Kallieri, Maria, Georgopoulou, Athina, Avarlis, Pantelis, Bakakos, Petros, Markopoulou, Katerina, Gaki, Eleni, Paspala, Asimina, Kyriakaki, Zacharoula, Gourgoulianis, Konstantinos I., Papiris, Spyridon, and Loukides, Stelios

Published
2022
Full Text
View/download PDF

7. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma

Author

Porsbjerg, Celeste M., Menzies-Gow, Andrew N., Tran, Trung N., Murray, Ruth B., Unni, Bindhu, Audrey Ang, Shi Ling, Alacqua, Marianna, Al-Ahmad, Mona, Al-Lehebi, Riyad, Altraja, Alan, Belevskiy, Andrey S., Björnsdóttir, Unnur S., Bourdin, Arnaud, Busby, John, Canonica, G. Walter, Christoff, George C., Cosio, Borja G., Costello, Richard W., FitzGerald, J. Mark, Fonseca, João A., Hansen, Susanne, Heaney, Liam G., Heffler, Enrico, Hew, Mark, Iwanaga, Takashi, Jackson, David J., Kocks, Janwillem W.H., Kallieri, Maria, Bruce Ko, Hsin-Kuo, Koh, Mariko Siyue, Larenas-Linnemann, Désirée, Lehtimäki, Lauri A., Loukides, Stelios, Lugogo, Njira, Maspero, Jorge, Papaioannou, Andriana I., Perez-de-Llano, Luis, Pitrez, Paulo Márcio, Popov, Todor A., Rasmussen, Linda M., Rhee, Chin Kook, Sadatsafavi, Mohsen, Schmid, Johannes, Siddiqui, Salman, Taillé, Camille, Taube, Christian, Torres-Duque, Carlos A., Ulrik, Charlotte, Upham, John W., Wang, Eileen, Wechsler, Michael E., Bulathsinhala, Lakmini, Carter, Victoria, Chaudhry, Isha, Eleangovan, Neva, Hosseini, Naeimeh, Rowlands, Mari-Anne, Price, David B., and van Boven, Job F.M.

Published
2022
Full Text
View/download PDF

8. Effects of menopause and fat mass in asthmatic inflammation.

Author

Papaporfyriou, Anastasia, Bartziokas, Kostas, Papachatzopoulou, Eftychia, Grapatsas, Kostas, Kallieri, Maria, Spathis, Aris, Steiropoulos, Paschalis, Bakakos, Petros, Papiris, Spyros, Loukides, Stelios, and Papaioannou, Andriana I.

Abstract

Introduction: Female hormones and obesity have an impact on women with asthma. We aimed to describe how these components affect asthma inflammatory processes. Methods: Sex hormones [FSH, LH, estradiol (E2), estrone (E1), testosterone and Δ4 androstenedione (A4)] and serum IL1β, IL13, IL17a, IL-5, IL6, TNF-a were measured from 11 to18 pre- and postmenopausal women with asthma. Results: Premenopausal normal weight women revealed higher levels of IL5 and IL17a than obese women on both days of the menstrual cycle (IL5: D1: 6.4 vs 1.4 pg/ml, p =.036 and D14: 3 vs 1.4 pg/ml, p =.045 and IL17a: D1: 13.7 pg/ml vs 10.6 pg/ml and D14: 12.4 pg/ml vs 10.6 pg/ml, p =.009, respectively). In premenopausal women on D1, Δ4 Androstenedione was positively correlated with IL1β (p =.016, r = 0.733), whereas on D14, Estradiol with IL1β (p =.009, r = −.768) and TNF-a with Testosterone (p =.004, r = −0.816), and Δ4 Androstenedione (p =.002, r = −0.841) negatively. In postmenopausal women, TNF-a was negatively associated with FSH (p =.004, r = −0.638), but positively with Testosterone (p =.025, r = 0.526) and IL10 also positively with Estradiol (p =.007, r = 0.610). Conclusion: Obesity shows a protective role in asthma through the suppression of IL5 and IL17. Estrogens seem to inhibit Th1 and Th2 inflammation, while androgens have a dual role with negative and positive correlations with neutrophilic biomarkers. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Lack of awareness for alpha-1 antitrypsin deficiency: A single-center retrospective study

Author

Zaneli, Stavrina, primary, Vafeiadis, Konstantinos, additional, Bartziokas, Konstantinos, additional, Anagnostopoulou, Christina, additional, Vontetsianos, Angelos, additional, Theloura, Vasiliki, additional, Schoini, Pinelopi, additional, Mavrea, Stavroula, additional, Antonogiannaki, Elvira-Markella, additional, Stagaki, Eleni, additional, Papaioannou, Andriana I., additional, and Bakakos, Petros, additional

Published
2024
Full Text
View/download PDF

11. Exercise Intolerance Is Associated with Cardiovascular Dysfunction in Long COVID-19 Syndrome.

Author

Vontetsianos, Angelos, Chynkiamis, Nikolaos, Gounaridi, Maria Ioanna, Anagnostopoulou, Christina, Lekka, Christiana, Zaneli, Stavroula, Anagnostopoulos, Nektarios, Oikonomou, Evangelos, Vavuranakis, Manolis, Rovina, Nikoletta, Papaioannou, Andriana I., Kaltsakas, Georgios, Koulouris, Nikolaos, and Vogiatzis, Ioannis

Subjects
GLOBAL longitudinal strain, POST-acute COVID-19 syndrome, EXERCISE physiology, EXERCISE tests, VENA cava inferior
Abstract

Background/Objectives: Cardiorespiratory complications are commonly reported among patients with long COVID-19 syndrome. However, their effects on exercise capacity remain inconclusive. We investigated the impact of long COVID-19 on exercise tolerance combining cardiopulmonary exercise testing (CPET) with resting echocardiographic data. Methods: Forty-two patients (55 ± 13 years), 149 ± 92 days post-hospital discharge, and ten healthy age-matched participants underwent resting echocardiography and an incremental CPET to the limit of tolerance. Left ventricular global longitudinal strain (LV-GLS) and the left ventricular ejection fraction (LVEF) were calculated to assess left ventricular systolic function. The E/e' ratio was estimated as a surrogate of left ventricular end-diastolic filling pressures. Tricuspid annular systolic velocity (SRV) was used to assess right ventricular systolic performance. Through tricuspid regurgitation velocity and inferior vena cava diameter, end-respiratory variations in systolic pulmonary artery pressure (PASP) were estimated. Peak work rate (WRpeak) and peak oxygen uptake (VO2peak) were measured via a ramp incremental symptom-limited CPET. Results: Compared to healthy participants, patients had a significantly (p < 0.05) lower LVEF (59 ± 4% versus 49 ± 5%) and greater left ventricular end-diastolic diameter (48 ± 2 versus 54 ± 5 cm). In patients, there was a significant association of E/e' with WRpeak (r = −0.325) and VO2peak (r = −0.341). SRV was significantly associated with WRpeak (r = 0.432) and VO2peak (r = 0.556). LV-GLS and PASP were significantly correlated with VO2peak (r = −0.358 and r = −0.345, respectively). Conclusions: In patients with long COVID-19 syndrome, exercise intolerance is associated with left ventricular diastolic performance, left ventricular end-diastolic pressure, PASP and SRV. These findings highlight the interrelationship of exercise intolerance with left and right ventricular performance in long COVID-19 syndrome. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Reply to “Exploring the long-term effects of biologic initiation in severe asthma: Insights from the International Severe Asthma Registry”

Author

Chen, Wenjia, primary, Tran, Trung N., additional, Sadatsafavi, Mohsen, additional, Murray, Ruth B., additional, Boon Wong, Nigel Chong, additional, Ali, Nasloon, additional, Ariti, Con, additional, Bulathsinhala, Lakmini, additional, Garcia Gil, Esther, additional, FitzGerald, J. Mark, additional, Alacqua, Marianna, additional, Al-Ahmad, Mona, additional, Altraja, Alan, additional, Al-Lehebi, Riyad, additional, Bhutani, Mohit, additional, Bjermer, Leif, additional, Bjerrum, Anne-Sofie, additional, Bourdin, Arnaud, additional, von Bülow, Anna, additional, Busby, John, additional, Canonica, Giorgio Walter, additional, Carter, Victoria, additional, Christoff, George C., additional, Cosio, Borja G., additional, Costello, Richard W., additional, Fonseca, João A., additional, Gibson, Peter G., additional, Yoo, Kwang Ha, additional, Heaney, Liam G., additional, Heffler, Enrico, additional, Hew, Mark, additional, Hilberg, Ole, additional, Hoyte, Flavia, additional, Iwanaga, Takashi, additional, Jackson, David J., additional, Jones, Rupert C., additional, Koh, Mariko Siyue, additional, Kuna, Piotr, additional, Larenas-Linnemann, Désirée, additional, Lehmann, Sverre, additional, Lehtimäki, Lauri, additional, Lyu, Juntao, additional, Mahboub, Bassam, additional, Maspero, Jorge, additional, Menzies-Gow, Andrew N., additional, Newell, Anthony, additional, Sirena, Concetta, additional, Papadopoulos, Nikolaos G., additional, Papaioannou, Andriana I., additional, Perez-de-Llano, Luis, additional, Perng (Steve), Diahn-Warng, additional, Peters, Matthew J., additional, Pfeffer, Paul E., additional, Porsbjerg, Celeste M., additional, Popov, Todor A., additional, Rhee, Chin Kook, additional, Salvi, Sundeep, additional, Taillé, Camille, additional, Taube, Christian, additional, Torres-Duque, Carlos A., additional, Ulrik, Charlotte, additional, Ra, Seung Won, additional, Wang, Eileen, additional, Wechsler, Michael E., additional, and Price, David B., additional

Published
2024
Full Text
View/download PDF

14. Switching from omalizumab to mepolizumab in severe asthmatics: A post hoc analysis of the RELight study

Author

Kallieri, Maria, primary, Papaioannou, Andriana I., additional, Zervas, Eleftherios, additional, Fouka, Evangelia, additional, Porpodis, Konstantinos, additional, Hadji Mitrova, Marija, additional, Tzortzaki, Eleni, additional, Makris, Michael, additional, Ntakoula, Maria, additional, Lyberopoulos, Panagiotis, additional, Dimakou, Katerina, additional, Koukidou, Sofia, additional, Ampelioti, Sevasti, additional, Papaporfyriou, Anastasia, additional, Katsoulis, Konstantinos, additional, Kipourou, Maria, additional, Rovina, Nikoletta, additional, Antoniou, Katerina, additional, Vittorakis, Stylianos, additional, Bakakos, Petros, additional, Steiropoulos, Paschalis, additional, Markopoulou, Katerina, additional, Avarlis, Panteleimon, additional, Papanikolaou, Ιlias C., additional, Markatos, Miltiadis, additional, Gaki, Eleni, additional, Samitas, Konstantinos, additional, Glynos, Konstantinos, additional, Papiris, Spyros A., additional, Papakosta, Despoina, additional, Tzanakis, Nikolaos, additional, Gaga, Mina, additional, Kostikas, Konstantinos, additional, and Loukides, Stelios, additional

Published
2023
Full Text
View/download PDF

15. Evaluation of the Acid–Base Status in Patients Admitted to the ICU Due to Severe COVID-19: Physicochemical versus Traditional Approaches

Author

Sotiropoulou, Zoi, primary, Antonogiannaki, Elvira Markela, additional, Koukaki, Evangelia, additional, Zaneli, Stavroula, additional, Bakakos, Agamemnon, additional, Vontetsianos, Angelos, additional, Anagnostopoulos, Nektarios, additional, Rovina, Nikoleta, additional, Loverdos, Konstantinos, additional, Tripolitsioti, Paraskevi, additional, Kyriakopoulou, Magdalini, additional, Pontikis, Konstantinos, additional, Bakakos, Petros, additional, Georgopoulos, Dimitrios, additional, and Papaioannou, Andriana I., additional

Published
2023
Full Text
View/download PDF

16. Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma

Author

Perez-de-Llano, Luis, primary, Scelo, Ghislaine, additional, Canonica, G. Walter, additional, Chen, Wenjia, additional, Henley, William, additional, Larenas-Linnemann, Désirée, additional, Peters, Matthesadatw J, additional, Pfeffer, Paul E., additional, Tran, Trung N., additional, Ulrik, Charlotte Suppli, additional, Popov, Todor A., additional, Sadatsafavi, Mohsen, additional, Hew, Mark, additional, Maspero, Jorge, additional, Gibson, Peter G., additional, Christoff, George C., additional, Fitzgerald, J. Mark, additional, Torres-Duque, Carlos A., additional, Porsbjerg, Celeste M., additional, Papadopoulos, Nikolaos G., additional, Papaioannou, Andriana I., additional, Heffler, Enrico, additional, Iwanaga, Takashi, additional, Al-Ahmad, Mona, additional, Kuna, Piotr, additional, Fonseca, João A, additional, Al-Lehebi, Riyad, additional, Rhee, Chin Kook, additional, Koh, Mariko Siyue, additional, Cosio, Borja G., additional, Perng (Steve), Diahn-Warng, additional, Mahboub, Bassam, additional, Menzies-Gow, Andrew N., additional, Jackson, David J., additional, Busby, John, additional, Heaney, Liam G., additional, Patel, Pujan H, additional, Wang, Eileen, additional, Wechsler, Michael E., additional, Altraja, Alan, additional, Lehtimäki, Lauri, additional, Bourdin, Arnaud, additional, Bjermer, Leif, additional, Bulathsinhala, Lakmini, additional, Carter, Victoria, additional, Murray, Ruth, additional, Beastall, Aaron, additional, Denton, Eve, additional, and Price, David B., additional

Published
2023
Full Text
View/download PDF

19. Switching from omalizumab to mepolizumab in severe asthmatics: A post hoc analysis of the RELight study.

Author

Kallieri, Maria, Papaioannou, Andriana I., Zervas, Eleftherios, Fouka, Evangelia, Porpodis, Konstantinos, Hadji Mitrova, Marija, Tzortzaki, Eleni, Makris, Michael, Ntakoula, Maria, Lyberopoulos, Panagiotis, Dimakou, Katerina, Koukidou, Sofia, Ampelioti, Sevasti, Papaporfyriou, Anastasia, Katsoulis, Konstantinos, Kipourou, Maria, Rovina, Nikoletta, Antoniou, Katerina, Vittorakis, Stylianos, and Bakakos, Petros

Subjects
*OMALIZUMAB, *ASTHMATICS, *BIOLOGICALS, *WHEEZE
Abstract

This article presents a post hoc analysis of the RELight study, which investigated the clinical benefit of switching from omalizumab to mepolizumab in patients with severe asthma. The study found that patients who switched to mepolizumab experienced a reduction in asthma exacerbations, improved asthma control, and a decrease in oral corticosteroid intake. These improvements were observed regardless of whether the patients had previously received omalizumab treatment. The findings suggest that switching therapies may be beneficial for patients with severe asthma who do not achieve optimal disease control. [Extracted from the article]

Published
2024
Full Text
View/download PDF

20. Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe Asthma

Author

Wechsler, Michael E, primary, Scelo, Ghislaine, additional, Larenas-Linnemann, Désirée E. S., additional, Torres-Duque, Carlos A., additional, Maspero, Jorge, additional, Tran, Trung N., additional, Murray, Ruth B., additional, Martin, Neil, additional, Menzies-Gow, Andrew N., additional, Hew, Mark, additional, Peters, Matthew J, additional, Gibson, Peter G, additional, Christoff, George C., additional, Popov, Todor A., additional, Côté, Andréanne, additional, Bergeron, Celine, additional, Dorscheid, Delbert, additional, FitzGerald, J Mark, additional, Chapman, Kenneth R, additional, Boulet, Louis Philippe, additional, Bhutani, Mohit, additional, Sadatsafavi, Mohsen, additional, Jiménez-Maldonado, Libardo, additional, Duran-Silva, Mauricio, additional, Rodriguez, Bellanid, additional, Celis-Preciado, Carlos Andres, additional, Cano-Rosales, Diana Jimena, additional, Solarte, Ivan, additional, Fernandez- Sanchez, Maria Jose, additional, Parada-Tovar, Patricia, additional, von Bülow, Anna, additional, Bjerrum, Anne Sofie, additional, Ulrik, Charlotte S, additional, Assing, Karin Dahl, additional, Rasmussen, Linda Makowska, additional, Hansen, Susanne, additional, Altraja, Alan, additional, Bourdin, Arnaud, additional, Taille, Camille, additional, Charriot, Jeremy, additional, Roche, Nicolas, additional, Papaioannou, Andriana I, additional, Kostikas, Konstantinos, additional, Papadopoulos, Nikolaos G., additional, Salvi, Sundeep, additional, Long, Deirdre, additional, Mitchell, Patrick D, additional, Costello, Richard, additional, Sirena, Concetta, additional, Cardini, Cristina, additional, Heffler, Enrico, additional, Puggioni, Francesca, additional, Canonica, Giorgio Walter, additional, Guida, Giuseppe, additional, Iwanaga, Takashi, additional, Al-Ahmad, Mona, additional, García, Ulises, additional, Kuna, Piotr, additional, Fonseca, João A., additional, Al-Lehebi, Riyad, additional, Koh, Mariko S., additional, Rhee, Chin Kook, additional, Cosio, Borja G, additional, Perez de Llano, Luis, additional, Perng, Diahn-Warng, additional, Huang, Erick Wan-Chun, additional, Wang, Hao-Chien, additional, Tsai, Ming-Ju, additional, Mahboub, Bassam, additional, Salameh, Laila Ibraheem Jaber, additional, Jackson, David J., additional, Busby, John, additional, Heaney, Liam G, additional, Pfeffer, Paul E., additional, Goddard, Amanda Grippen, additional, Wang, Eileen, additional, Hoyte, Flavia C. L., additional, Chapman, Nicholas M, additional, Katial, Rohit, additional, Carter, Victoria, additional, Bulathsinhala, Lakmini, additional, Eleangovan, Neva, additional, Ariti, Con, additional, Lyu, Juntao, additional, Porsbjerg, Celeste, additional, and Price, David B., additional

Published
2023
Full Text
View/download PDF

21. Patients Hospitalized for COVID-19 in the Periods of Delta and Omicron Variant Dominance in Greece: Determinants of Severity and Mortality

Author

Karageorgou, Vagia, primary, Papaioannou, Andriana I., additional, Kallieri, Maria, additional, Blizou, Myrto, additional, Lampadakis, Stefanos, additional, Sfika, Maria, additional, Krouskos, Antonios, additional, Papavasileiou, Vasileios, additional, Strakosha, Franceska, additional, Vandorou, Kalliopi Theoni, additional, Siozos, Pavlos, additional, Moustaka Christodoulou, Marina, additional, Kontonasiou, Georgia, additional, Apollonatou, Vasiliki, additional, Antonogiannaki, Elvira Markella, additional, Kyriakopoulos, Christos, additional, Aggelopoulou, Christina, additional, Chronis, Christos, additional, Kostikas, Konstantinos, additional, Koukaki, Evangelia, additional, Sotiropoulou, Zoi, additional, Athanasopoulou, Athanasia, additional, Bakakos, Petros, additional, Schoini, Pinelopi, additional, Alevrakis, Emmanouil, additional, Poupos, Sotirios, additional, Chondrou, Evangelia, additional, Tsoukalas, Dionisios, additional, Chronaiou, Alexia, additional, Tsoukalas, George, additional, Koukidou, Sofia, additional, Hillas, Georgios, additional, Dimakou, Katerina, additional, Roukas, Konstantinos, additional, Nakou, Ifigeneia, additional, Chloros, Diamantis, additional, Fouka, Evangelia, additional, Papiris, Spyros A., additional, and Loukides, Stelios, additional

Published
2023
Full Text
View/download PDF

22. Autoimmune Pulmonary Alveolar Proteinosis (aPAP) in Greece: 20 years in progress

Author

Papiris, Spyros A, primary, Kallieri, Maria, additional, Kolilekas, Lykourgos, additional, Papadaki, Georgia, additional, Verykakis, Emmanouil, additional, Kontonasiou, Georgia, additional, Papaioannou, Andriana I, additional, Bouros, Demosthenes, additional, Apollonatou, Vasiliki, additional, Antonogiannaki, Elvira-Markela, additional, Lyberopoulos, Panagiotis, additional, Roussakis, Nikolaos, additional, Douros, Konstantinos, additional, Schams, Andrea, additional, Griese, Matthias, additional, and Manali, Effrosyni D., additional

Published
2023
Full Text
View/download PDF

23. Real-world associations between outcomes and biomarkers in severe asthma patients treated with biologics

Author

Townend, John, primary, Tran, Trung N, additional, Martin, Neil, additional, Menzies-Gow, Andrew N., additional, Wang, Eileen, additional, Wechsler, Michael E., additional, Canonica, Giorgio Walter, additional, Heffler, Enrico, additional, Perez-De-Llano, Luis, additional, Cosio, Borja G., additional, Hew, Mark, additional, Peters, Matthew, additional, Gibson, Peter G., additional, Bosnic-Anticevich, Sinthia, additional, Heaney, Liam G., additional, Jackson, David J., additional, Pfeffer, Paul E., additional, Busby, John, additional, Salvi, Sundeep, additional, Christoff, George C., additional, Popov, Todor A., additional, Porsbjerg, Celeste M., additional, Torres-Duque, Carlos A., additional, Al-Lehebi, Riyad, additional, Al-Ahmad, Mona, additional, Perng, Diahn-Warng, additional, Bergeron, Celine, additional, Sadatsafavi, Mohsen, additional, Mahboub, Bassam, additional, Iwanaga, Takashi, additional, Maspero, Jorge, additional, Kuna, Piotr, additional, Chin, Kook Rhee, additional, Larenas-Linnemann, Désirée, additional, Papadopoulos, Nikolaos G., additional, Papaioannou, Andriana I., additional, Fonseca, João A., additional, Siyue Koh, Mariko, additional, Costello, Richard W., additional, and Price, David, additional

Published
2023
Full Text
View/download PDF

24. The clinical experience of patients with severe asthma and previous treatment with omalizumab, choosing mepolizumab in Greece.

Author

Kallieri, Maria, primary, Papaioannou, Andriana I., additional, Zervas, Eleftherios, additional, Fouka, Evangelia, additional, Porpodis, Konstantinos, additional, Hadji Mitrova, Marija, additional, Tzortzaki, Eleni, additional, Makris, Michael, additional, Ntakoula, Maria, additional, Lyberopoulos, Panagiotis, additional, Dimakou, Katerina, additional, Koukidou, Sofia, additional, Ampelioti, Sevasti, additional, Papaporfyriou, Anastasia, additional, Katsoulis, Konstantinos, additional, Kipourou, Maria, additional, Rovina, Nikoletta, additional, Antoniou, Katerina, additional, Vittorakis, Stylianos, additional, Bakakos, Petros, additional, Steiropoulos, Paschalis, additional, Markopoulou, Katerina, additional, Avarlis, Panteleimon, additional, Papanikolaou, Ιlias C., additional, Markatos, Miltiadis, additional, Gaki, Eleni, additional, Samitas, Konstantinos, additional, Glynos, Konstantinos, additional, Papiris, Spyros A., additional, Papakosta, Despoina, additional, Tzanakis, Nikolaos, additional, Gaga, Mina, additional, Kostikas, Konstantinos, additional, and Loukides, Stelios, additional

Published
2023
Full Text
View/download PDF

27. Serum Surfactant Protein Levels in Patients Admitted to the Hospital with Acute COPD Exacerbation

Author

Papaioannou, Andriana I., Konstantelou, Elisavet, Papaporfyriou, Anastasia, Bartziokas, Konstantinos, Spathis, Aris, Bakakos, Petros, and Loukides, Stelios

Subjects
Chronic obstructive lung disease -- Genetic aspects -- Diagnosis -- Care and treatment -- Patient outcomes -- Research, Biological markers -- Physiological aspects -- Research, Health
Abstract

Surfactant proteins (SPs) have been studied in COPD patients as biomarkers of disease severity and as predictive factors of unfavorable outcomes. The aim of this exploratory study was to evaluate serum levels of SP-A, SP-B, SP-C, and SP-D in patients with COPD both during AECOPD and in stability and to test their possible associations with disease severity and with the development of new exacerbation events. 20 consecutive COPD patients hospitalized for AECOPD were included. Serum SP levels were measured on admission, at discharge, and on stability. SP-A levels were significantly lower both on admission and at discharge in patients with early relapse compared to those with late or no relapse (29.2 ± 9.1 vs. 43.9 ± 16.9 ng/ml, p = 0.037, and 24.3 ± 2.8 vs. 39.3 ± 14.2 ng/ml, p = 0.011, respectively). SP-B levels were found to have a trend to be higher at discharge and significantly higher on stability in patients experiencing an early relapse compared to those with late or no relapse (52.5 ± 31.6 vs. 31.4 ± 32.3 ng/ml, p = 0.052 and 64.8 ± 32.6 vs. 32.8 ± 25.6 ng/ml, p = 0.024, respectively). Finally, the ROC analysis showed that serum SP-A, SP-B, and SP-C levels at discharge, seemed to be significant predictors of early relapse. Our conclusion is that serum levels of SPs might be related to disease outcomes in COPD patients., Author(s): Andriana I. Papaioannou [sup.1] , Elisavet Konstantelou [sup.2] , Anastasia Papaporfyriou [sup.2] , Konstantinos Bartziokas [sup.1] , Aris Spathis [sup.3] , Petros Bakakos [sup.2] , Stelios Loukides [sup.1] , [...]

Published
2018
Full Text
View/download PDF

29. Eosinopenia as a Prognostic Biomarker for Noninvasive Ventilation Use in COPD Exacerbations

Author

Bartziokas, Konstantinos, primary, Papathanasiou, Evgenia, additional, Papaioannou, Andriana I., additional, Papanikolaou, Ilias, additional, Antonakis, Emmanouil, additional, Makou, Ioanna, additional, Hillas, Georgios, additional, Karampitsakos, Theodoros, additional, Papaioannou, Ourania, additional, Dimakou, Katerina, additional, Apollonatou, Vasiliki, additional, Verykokou, Galateia, additional, Papiris, Spyros, additional, Bakakos, Petros, additional, Loukides, Stelios, additional, and Kostikas, Konstantinos, additional

Published
2023
Full Text
View/download PDF

30. Comparative effectiveness of anti‐IL5 and anti‐IgE biologic classes in patients with severe asthma eligible for both

Author

Pfeffer, Paul E., primary, Ali, Nasloon, additional, Murray, Ruth, additional, Ulrik, Charlotte, additional, Tran, Trung N., additional, Maspero, Jorge, additional, Peters, Matthew, additional, Christoff, George C., additional, Sadatsafavi, Mohsen, additional, Torres‐Duque, Carlos A., additional, Altraja, Alan, additional, Lehtimäki, Lauri, additional, Papadopoulos, Nikolaos G., additional, Salvi, Sundeep, additional, Costello, Richard W., additional, Cushen, Breda, additional, Heffler, Enrico, additional, Iwanaga, Takashi, additional, Al‐Ahmad, Mona, additional, Larenas‐Linnemann, Désirée, additional, Kuna, Piotr, additional, Fonseca, João A., additional, Al‐Lehebi, Riyad, additional, Rhee, Chin Kook, additional, Perez‐de‐Llano, Luis, additional, Perng Steve, Diahn‐Warng, additional, Mahboub, Bassam, additional, Wang, Eileen, additional, Goh, Celine, additional, Lyu, Juntao, additional, Newell, Anthony, additional, Alacqua, Marianna, additional, Belevskiy, Andrey S., additional, Bhutani, Mohit, additional, Bjermer, Leif, additional, Bjornsdottir, Unnur, additional, Bourdin, Arnaud, additional, Bulow, Anna von, additional, Busby, John, additional, Canonica, Giorgio Walter, additional, Cosio, Borja G., additional, Dorscheid, Delbert R., additional, Muñoz‐Esquerre, Mariana, additional, FitzGerald, J. Mark, additional, Gil, Esther Garcia, additional, Gibson, Peter G., additional, Heaney, Liam G., additional, Hew, Mark, additional, Hilberg, Ole, additional, Hoyte, Flavia, additional, Jackson, David J., additional, Koh, Mariko Siyue, additional, Ko, Hsin‐Kuo Bruce, additional, Lee, Jae Ha, additional, Lehmann, Sverre, additional, Chaves Loureiro, Cláudia, additional, Lúðvíksdóttir, Dóra, additional, Menzies‐Gow, Andrew N., additional, Mitchell, Patrick, additional, Papaioannou, Andriana I., additional, Popov, Todor A., additional, Porsbjerg, Celeste M., additional, Salameh, Laila, additional, Sirena, Concetta, additional, Taillé, Camille, additional, Taube, Christian, additional, Tohda, Yuji, additional, Wechsler, Michael E., additional, and Price, David B., additional

Published
2023
Full Text
View/download PDF

31. Impact of Inititing Biologics in Patients With Severe Asthma on Long-term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER):Data From the International Severe Asthma Registry

Author

Chen, Wenjia, Tran, Trung N., Sadatsafavi, Mohsen, Murray, Ruth, Wong, Nigel Chong Boon, Ali, Nasloon, Ariti, Con, Bulathsinhala, Lakmini, Gil, Esther Garcia, FitzGerald, J. Mark, Alacqua, Marianna, Al-Ahmad, Mona, Altraja, Alan, Al-Lehebi, Riyad, Bhutani, Mohit, Bjermer, Leif, Bjerrum, Anne Sofie, Bourdin, Arnaud, von Bülow, Anna, Busby, John, Canonica, Giorgio Walter, Carter, Victoria, Christoff, George C., Cosio, Borja G., Costello, Richard W., Fonseca, João A., Gibson, Peter G., Yoo, Kwang Ha, Heaney, Liam G., Heffler, Enrico, Hew, Mark, Hilberg, Ole, Hoyte, Flavia, Iwanaga, Takashi, Jackson, David J., Jones, Rupert C., Koh, Mariko Siyue, Kuna, Piotr, Larenas-Linnemann, Désirée, Lehmann, Sverre, Lehtimäki, Lauri, Lyu, Juntao, Mahboub, Bassam, Maspero, Jorge, Menzies-Gow, Andrew N., Newell, Anthony, Sirena, Concetta, Papadopoulos, Nikolaos G., Papaioannou, Andriana I., Perez-de-Llano, Luis, Perng (Steve), Diahn Warng, Peters, Matthew, Pfeffer, Paul E., Porsbjerg, Celeste M., Popov, Todor A., Rhee, Chin Kook, Salvi, Sundeep, Taillé, Camille, Taube, Christian, Torres-Duque, Carlos A., Ulrik, Charlotte, Ra, Seung Won, Wang, Eileen, Wechsler, Michael E., Price, David B., Chen, Wenjia, Tran, Trung N., Sadatsafavi, Mohsen, Murray, Ruth, Wong, Nigel Chong Boon, Ali, Nasloon, Ariti, Con, Bulathsinhala, Lakmini, Gil, Esther Garcia, FitzGerald, J. Mark, Alacqua, Marianna, Al-Ahmad, Mona, Altraja, Alan, Al-Lehebi, Riyad, Bhutani, Mohit, Bjermer, Leif, Bjerrum, Anne Sofie, Bourdin, Arnaud, von Bülow, Anna, Busby, John, Canonica, Giorgio Walter, Carter, Victoria, Christoff, George C., Cosio, Borja G., Costello, Richard W., Fonseca, João A., Gibson, Peter G., Yoo, Kwang Ha, Heaney, Liam G., Heffler, Enrico, Hew, Mark, Hilberg, Ole, Hoyte, Flavia, Iwanaga, Takashi, Jackson, David J., Jones, Rupert C., Koh, Mariko Siyue, Kuna, Piotr, Larenas-Linnemann, Désirée, Lehmann, Sverre, Lehtimäki, Lauri, Lyu, Juntao, Mahboub, Bassam, Maspero, Jorge, Menzies-Gow, Andrew N., Newell, Anthony, Sirena, Concetta, Papadopoulos, Nikolaos G., Papaioannou, Andriana I., Perez-de-Llano, Luis, Perng (Steve), Diahn Warng, Peters, Matthew, Pfeffer, Paul E., Porsbjerg, Celeste M., Popov, Todor A., Rhee, Chin Kook, Salvi, Sundeep, Taillé, Camille, Taube, Christian, Torres-Duque, Carlos A., Ulrik, Charlotte, Ra, Seung Won, Wang, Eileen, Wechsler, Michael E., and Price, David B.

Abstract

Background Effectiveness of biologics has neither been established in patients with high oral corticosteroid exposure (HOCS) nor been compared with effectiveness of continuing with HOCS alone. Objective To examine the effectiveness of initiating biologics in a large, real-world cohort of adult patients with severe asthma and HOCS. Methods This was a propensity score–matched, prospective cohort study using data from the International Severe Asthma Registry. Between January 2015 and February 2021, patients with severe asthma and HOCS (long-term OCSs for ≥1 year or ≥4 courses of rescue OCSs within a 12-month period) were identified. Biologic initiators were identified and, using propensity scores, matched 1:1 with noninitiators. The impact of biologic initiation on asthma outcomes was assessed using generalized linear models. Results We identified 996 matched pairs of patients. Both groups improved over the 12-month follow-up period, but improvement was greater for biologic initiators. Biologic initiation was associated with a 72.9% reduction in the average number of exacerbations per year versus noninitiators (0.64 vs 2.06; rate ratio, 0.27 [95% CI, 0.10-0.71]). Biologic initiators were 2.2 times more likely than noninitiators to take a daily long-term OCS dose of less than 5 mg (risk probability, 49.6% vs 22.5%; P = .002) and had a lower risk of asthma-related emergency department visits (relative risk, 0.35 [95% CI, 0.21-0.58]; rate ratio, 0.26 [0.14-0.48]) and hospitalizations (relative risk, 0.31 [95% CI, 0.18-0.52]; rate ratio, 0.25 [0.13-0.48]). Conclusions In a real-world setting, including patients with severe asthma and HOCS from 19 countries, and within an environment of clinical improvement, initiation of biologics was associated with further improvements across multiple asthma outcomes, including exacerbation rate, OCS exposure, and health care resource utilization., Background: Effectiveness of biologics has neither been established in patients with high oral corticosteroid exposure (HOCS) nor been compared with effectiveness of continuing with HOCS alone. Objective: To examine the effectiveness of initiating biologics in a large, real-world cohort of adult patients with severe asthma and HOCS. Methods: This was a propensity score–matched, prospective cohort study using data from the International Severe Asthma Registry. Between January 2015 and February 2021, patients with severe asthma and HOCS (long-term OCSs for ≥1 year or ≥4 courses of rescue OCSs within a 12-month period) were identified. Biologic initiators were identified and, using propensity scores, matched 1:1 with noninitiators. The impact of biologic initiation on asthma outcomes was assessed using generalized linear models. Results: We identified 996 matched pairs of patients. Both groups improved over the 12-month follow-up period, but improvement was greater for biologic initiators. Biologic initiation was associated with a 72.9% reduction in the average number of exacerbations per year versus noninitiators (0.64 vs 2.06; rate ratio, 0.27 [95% CI, 0.10-0.71]). Biologic initiators were 2.2 times more likely than noninitiators to take a daily long-term OCS dose of less than 5 mg (risk probability, 49.6% vs 22.5%; P = .002) and had a lower risk of asthma-related emergency department visits (relative risk, 0.35 [95% CI, 0.21-0.58]; rate ratio, 0.26 [0.14-0.48]) and hospitalizations (relative risk, 0.31 [95% CI, 0.18-0.52]; rate ratio, 0.25 [0.13-0.48]). Conclusions: In a real-world setting, including patients with severe asthma and HOCS from 19 countries, and within an environment of clinical improvement, initiation of biologics was associated with further improvements across multiple asthma outcomes, including exacerbation rate, OCS exposure, and health care resource utilization.

Published
2023

32. Comparative effectiveness of anti-IL5 and anti-IgE biologic classes in patients with severe asthma eligible for both

Author

Pfeffer, Paul E., Ali, Nasloon, Murray, Ruth, Ulrik, Charlotte, Tran, Trung N., Maspero, Jorge, Peters, Matthew, Christoff, George C., Sadatsafavi, Mohsen, Torres-Duque, Carlos A., Altraja, Alan, Lehtimäki, Lauri, Papadopoulos, Nikolaos G, Salvi, Sundeep, Costello, Richard W., Cushen, Breda, Heffler, Enrico, Iwanaga, Takashi, Al-Ahmad, Mona, Larenas-Linnemann, Désirée, Kuna, Piotr, Fonseca, João A., Al-Lehebi, Riyad, Rhee, Chin Kook, Perez-de-Llano, Luis, Perng Steve, Diahn Warng, Mahboub, Bassam, Wang, Eileen, Goh, Celine, Lyu, Juntao, Newell, Anthony, Alacqua, Marianna, Belevskiy, Andrey S., Bhutani, Mohit, Bjermer, Leif, Bjornsdottir, Unnur, Bourdin, Arnaud, Bulow, Anna von, Busby, John, Canonica, Giorgio Walter, Cosio, Borja G., Dorscheid, Delbert R., Muñoz-Esquerre, Mariana, FitzGerald, J. Mark, Gil, Esther Garcia, Gibson, Peter G., Heaney, Liam G., Hew, Mark, Hilberg, Ole, Hoyte, Flavia, Jackson, David J., Koh, Mariko Siyue, Ko, Hsin Kuo Bruce, Lee, Jae Ha, Lehmann, Sverre, Chaves Loureiro, Cláudia, Lúðvíksdóttir, Dóra, Menzies-Gow, Andrew N., Mitchell, Patrick, Papaioannou, Andriana I., Popov, Todor A., Porsbjerg, Celeste M., Salameh, Laila, Sirena, Concetta, Taillé, Camille, Taube, Christian, Tohda, Yuji, Wechsler, Michael E., Price, David B., Pfeffer, Paul E., Ali, Nasloon, Murray, Ruth, Ulrik, Charlotte, Tran, Trung N., Maspero, Jorge, Peters, Matthew, Christoff, George C., Sadatsafavi, Mohsen, Torres-Duque, Carlos A., Altraja, Alan, Lehtimäki, Lauri, Papadopoulos, Nikolaos G, Salvi, Sundeep, Costello, Richard W., Cushen, Breda, Heffler, Enrico, Iwanaga, Takashi, Al-Ahmad, Mona, Larenas-Linnemann, Désirée, Kuna, Piotr, Fonseca, João A., Al-Lehebi, Riyad, Rhee, Chin Kook, Perez-de-Llano, Luis, Perng Steve, Diahn Warng, Mahboub, Bassam, Wang, Eileen, Goh, Celine, Lyu, Juntao, Newell, Anthony, Alacqua, Marianna, Belevskiy, Andrey S., Bhutani, Mohit, Bjermer, Leif, Bjornsdottir, Unnur, Bourdin, Arnaud, Bulow, Anna von, Busby, John, Canonica, Giorgio Walter, Cosio, Borja G., Dorscheid, Delbert R., Muñoz-Esquerre, Mariana, FitzGerald, J. Mark, Gil, Esther Garcia, Gibson, Peter G., Heaney, Liam G., Hew, Mark, Hilberg, Ole, Hoyte, Flavia, Jackson, David J., Koh, Mariko Siyue, Ko, Hsin Kuo Bruce, Lee, Jae Ha, Lehmann, Sverre, Chaves Loureiro, Cláudia, Lúðvíksdóttir, Dóra, Menzies-Gow, Andrew N., Mitchell, Patrick, Papaioannou, Andriana I., Popov, Todor A., Porsbjerg, Celeste M., Salameh, Laila, Sirena, Concetta, Taillé, Camille, Taube, Christian, Tohda, Yuji, Wechsler, Michael E., and Price, David B.

Abstract

Background Patients with severe asthma may present with characteristics representing overlapping phenotypes, making them eligible for more than one class of biologic. Our aim was to describe the profile of adult patients with severe asthma eligible for both anti-IgE and anti-IL5/5R and to compare the effectiveness of both classes of treatment in real life. Methods This was a prospective cohort study that included adult patients with severe asthma from 22 countries enrolled into the International Severe Asthma registry (ISAR) who were eligible for both anti-IgE and anti-IL5/5R. The effectiveness of anti-IgE and anti-IL5/5R was compared in a 1:1 matched cohort. Exacerbation rate was the primary effectiveness endpoint. Secondary endpoints included long-term-oral corticosteroid (LTOCS) use, asthma-related emergency room (ER) attendance, and hospital admissions. Results In the matched analysis (n = 350/group), the mean annualized exacerbation rate decreased by 47.1% in the anti-IL5/5R group and 38.7% in the anti-IgE group. Patients treated with anti-IL5/5R were less likely to experience a future exacerbation (adjusted IRR 0.76; 95% CI 0.64, 0.89; p < 0.001) and experienced a greater reduction in mean LTOCS dose than those treated with anti-IgE (37.44% vs. 20.55% reduction; p = 0.023). There was some evidence to suggest that patients treated with anti-IL5/5R experienced fewer asthma-related hospitalizations (IRR 0.64; 95% CI 0.38, 1.08), but not ER visits (IRR 0.94, 95% CI 0.61, 1.43). Conclusions In real life, both anti-IgE and anti-IL5/5R improve asthma outcomes in patients eligible for both biologic classes; however, anti-IL5/5R was superior in terms of reducing asthma exacerbations and LTOCS use., Background: Patients with severe asthma may present with characteristics representing overlapping phenotypes, making them eligible for more than one class of biologic. Our aim was to describe the profile of adult patients with severe asthma eligible for both anti-IgE and anti-IL5/5R and to compare the effectiveness of both classes of treatment in real life. Methods: This was a prospective cohort study that included adult patients with severe asthma from 22 countries enrolled into the International Severe Asthma registry (ISAR) who were eligible for both anti-IgE and anti-IL5/5R. The effectiveness of anti-IgE and anti-IL5/5R was compared in a 1:1 matched cohort. Exacerbation rate was the primary effectiveness endpoint. Secondary endpoints included long-term-oral corticosteroid (LTOCS) use, asthma-related emergency room (ER) attendance, and hospital admissions. Results: In the matched analysis (n = 350/group), the mean annualized exacerbation rate decreased by 47.1% in the anti-IL5/5R group and 38.7% in the anti-IgE group. Patients treated with anti-IL5/5R were less likely to experience a future exacerbation (adjusted IRR 0.76; 95% CI 0.64, 0.89; p < 0.001) and experienced a greater reduction in mean LTOCS dose than those treated with anti-IgE (37.44% vs. 20.55% reduction; p = 0.023). There was some evidence to suggest that patients treated with anti-IL5/5R experienced fewer asthma-related hospitalizations (IRR 0.64; 95% CI 0.38, 1.08), but not ER visits (IRR 0.94, 95% CI 0.61, 1.43). Conclusions: In real life, both anti-IgE and anti-IL5/5R improve asthma outcomes in patients eligible for both biologic classes; however, anti-IL5/5R was superior in terms of reducing asthma exacerbations and LTOCS use.

Published
2023

35. Epidemiology and Immunopathogenesis of Virus Associated Asthma Exacerbations.

Author

Bakakos, Agamemnon, Sotiropoulou, Zoi, Vontetsianos, Angelos, Zaneli, Stavroula, Papaioannou, Andriana I, and Bakakos, Petros

Subjects
HUMAN metapneumovirus infection, ASTHMATICS, DISEASE exacerbation, RESPIRATORY syncytial virus, PATIENT experience, VIRUS diseases
Abstract

Asthma is a common airway disease, affecting millions of people worldwide. Although most asthma patients experience mild symptoms, it is characterized by variable airflow limitation, which can occasionally become life threatening in the case of a severe exacerbation. The commonest triggers of asthma exacerbations in both children and adults are viral infections. In this review article, we will try to investigate the most common viruses triggering asthma exacerbations and their role in asthma immunopathogenesis, since viral infections in young adults are thought to trigger the development of asthma either right away after the infection or at a later stage of their life. The commonest viral pathogens associated with asthma include the respiratory syncytial virus, rhinoviruses, influenza and parainfluenza virus, metapneumovirus and coronaviruses. All these viruses exploit different molecular pathways to infiltrate the host. Asthmatics are more prone to severe viral infections due to their unique inflammatory response, which is mostly characterized by T2 cytokines. Unlike the normal T1 high response to viral infection, asthmatics with T2 high inflammation are less potent in containing a viral infection. Inhaled and/or systematic corticosteroids and bronchodilators remain the cornerstone of asthma exacerbation treatment, and although many targeted therapies which block molecules that viruses use to infect the host have been used in a laboratory level, none has been yet approved for clinical use. Nevertheless, further understanding of the unique pathway that each virus follows to infect an individual may be crucial in the development of targeted therapies for the commonest viral pathogens to effectively prevent asthma exacerbations. Finally, biologic therapies resulted in a complete change of scenery in the treatment of severe asthma, especially with a T2 high phenotype. All available data suggest that monoclonal antibodies are safe and able to drastically reduce the rate of viral asthma exacerbations. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

38. Nursing home elderly patients hospitalized for COVID ‐19: Characteristics and predictors of outcomes

Author

Verykokou, Galateia, primary, Apollonatou, Vasiliki, additional, Papaioannou, Andriana I, additional, Vogiatzoglou, Anastasios, additional, Roukas, Konstantinos, additional, Kyriakopoulos, Christos, additional, Chronis, Christos, additional, Aggelopoulou, Christina, additional, Gundogdu, Deniz, additional, Schoini, Pinelopi, additional, Chloros, Diamantis, additional, Kavatha, Dimitra, additional, Manali, Effrosyni D, additional, Papiris, Spyros A, additional, Tsoukalas, George, additional, Kostikas, Konstantinos, additional, Fouka, Evangelia, additional, Boumpas, Dimitrios, additional, and Loukides, Stelios, additional

Published
2022
Full Text
View/download PDF

39. Greek Guidelines for the Management of COPD, a Proposal of a Holistic Approach Based on the needs of the Greek Community

Author

Tzanakis, Nikolaos, primary, Kosmas, Epameinontas, additional, Papaioannou, Andriana I., additional, Hillas, Georgios, additional, Zervas, Eleftherios, additional, Loukides, Stelios, additional, Bakakos, Petros, additional, Katsaounou, Paraskevi, additional, Boutou, Afroditi, additional, Perlikos, Photis, additional, Rovina, Nikolleta, additional, Dimakou, Katerina, additional, Steiropoulos, Paschalis, additional, Stratakos, Grigorios, additional, Emmanouil, Philipos, additional, Tryfon, Stavros, additional, and Koulouris, Nikolaos, additional

Published
2022
Full Text
View/download PDF

44. Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy

Author

Chen, Wenjia, primary, Sadatsafavi, Mohsen, additional, Tran, Trung N, additional, Murray, Ruth B, additional, Wong, Chong Boon Nigel, additional, Ali, Nasloon, additional, Ariti, Cono, additional, Garcia Gil, Esther, additional, Newell, Anthony, additional, Alacqua, Marianna, additional, Al-Ahmad, Mona, additional, Altraja, Alan, additional, Al-Lehebi, Riyad, additional, Bhutani, Mohit, additional, Bjermer, Leif, additional, Bjerrum, Anne Sofie, additional, Bourdin, Arnaud, additional, Bulathsinhala, Lakmini, additional, von Bülow, Anna, additional, Busby, John, additional, Canonica, Giorgio Walter, additional, Carter, Victoria, additional, Christoff, George C, additional, Cosio, Borja G, additional, Costello, Richard W, additional, FitzGerald, J Mark, additional, Fonseca, João A, additional, Yoo, Kwang Ha, additional, Heaney, Liam G, additional, Heffler, Enrico, additional, Hew, Mark, additional, Hilberg, Ole, additional, Hoyte, Flavia, additional, Iwanaga, Takashi, additional, Jackson, David J, additional, Jones, Rupert C, additional, Koh, Mariko Siyue, additional, Kuna, Piotr, additional, Larenas-Linnemann, Désirée, additional, Lehmann, Sverre, additional, Lehtimäki, Lauri A, additional, Lyu, Juntao, additional, Mahboub, Bassam, additional, Maspero, Jorge, additional, Menzies-Gow, Andrew N, additional, Sirena, Concetta, additional, Papadopoulos, Nikolaos, additional, Papaioannou, Andriana I, additional, Pérez de Llano, Luis, additional, Perng, Diahn-Warng, additional, Peters, Matthew, additional, Pfeffer, Paul E, additional, Porsbjerg, Celeste M, additional, Popov, Todor A, additional, Rhee, Chin Kook, additional, Salvi, Sundeep, additional, Taillé, Camille, additional, Taube, Christian, additional, Torres-Duque, Carlos A, additional, Ulrik, Charlotte S, additional, Ra, Seung Won, additional, Wang, Eileen, additional, Wechsler, Michael E, additional, and Price, David B, additional

Published
2022
Full Text
View/download PDF

47. Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy.

Author

Papaporfyriou, Anastasia, Bartziokas, Konstantinos, Gompelmann, Daniela, Idzko, Marco, Fouka, Evangelia, Zaneli, Stavrina, Bakakos, Petros, Loukides, Stelios, and Papaioannou, Andriana I.

Subjects
COMORBIDITY, CHRONIC obstructive pulmonary disease, CARDIOVASCULAR diseases, DISEASE risk factors, DIAGNOSIS
Abstract

Chronic obstructive pulmonary disease (COPD) is considered one of the leading causes of mortality. Cardiovascular comorbidities are diagnosed often in COPD patients, not only because of the common risk factors these two diseases share, but also because of the systemic inflammation which characterizes COPD and has deleterious effects in the cardiovascular system. The comorbid cardiovascular diseases in COPD result in several difficulties in the holistic treatment of these patients and affect outcomes such as morbidity and mortality. Several studies have reported that mortality from cardiovascular causes is common among COPD patients, while the risk for acute cardiovascular events increases during COPD exacerbations and remains high for a long time even after recovery. In this review, we focus on the prevalence of cardiovascular comorbidities in COPD patients, presenting the evidence regarding the interaction of the pathophysiological pathways which characterize each disease. Furthermore, we summarize information regarding the effects of cardiovascular treatment on COPD outcomes and vice versa. Finally, we present the current evidence regarding the impact of cardiovascular comorbidities on exacerbations, quality of life and survival of COPD patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Sestrin 2 levels are associated with emphysematous phenotype of COPD

Author

Angelakis, Leonidas, primary, Papaioannou, Andriana I., additional, Papathanasiou, Evgenia, additional, Mazioti, Argiro, additional, Kallieri, Maria, additional, Papatheodorou, George, additional, Patentalakis, George, additional, Hillas, Georgios, additional, Papiris, Spyridon, additional, Koulouris, Nikolaos, additional, Loukides, Stelios, additional, and Bakakos, Petros, additional

Published
2022
Full Text
View/download PDF

50. COVID-19 in patients with pulmonary alveolar proteinosis: a European multicentre study

Author

Papiris, Spyros A., primary, Campo, Ilaria, additional, Mariani, Francesca, additional, Kallieri, Maria, additional, Kolilekas, Lykourgos, additional, Papaioannou, Andriana I., additional, Gonca Chousein, Efsun, additional, Cetinkaya, Erdogan, additional, Bonella, Francesco, additional, Borie, Raphael, additional, Kokosi, Maria, additional, Pickworth, Thomas, additional, Molina-Molina, Maria, additional, Gasa, Mercè, additional, Radzikowska, Elżbieta, additional, Fijolek, Justyna, additional, Jouneau, Stéphane, additional, Gomez, Emmanuel, additional, McCarthy, Cormac, additional, Bendstrup, Elisabeth, additional, Piotrowski, Wojciech J., additional, Pabary, Rishi, additional, Hadchouel, Alice, additional, Coolen-Allou, Nathalie, additional, Alfaro, Tiago, additional, Robalo Cordeiro, Carlos, additional, Antonogiannaki, Elvira-Markela, additional, Tomos, Ioannis P., additional, Papakosta, Despoina, additional, Kontakiotis, Theodoros, additional, Panagiotou, Panagiota, additional, Douros, Konstantinos, additional, Schams, Andrea, additional, Lettieri, Sara, additional, Papaevangelou, Vassiliki, additional, Kanaka-Gantenbein, Christina, additional, Karakatsani, Anna, additional, Loukides, Stelios, additional, Costabel, Ulrich, additional, Crestani, Bruno, additional, Morgan, Cliff, additional, Tazawa, Ryushi, additional, Bush, Andrew, additional, Griese, Matthias, additional, and Manali, Effrosyni D., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results